InSilico lands drug discovery deal after Hong Kong IPO
The developer of AI-enabled drugs could get up to $888 million from the new deal but, without any viable products yet, its revenues rely on partner payments Key Takeaways: The…
Recent Articles
RELATED ARTICLES
-
XtalPi scores landmark deal for AI drug discovery
2228.HK - Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
-
BRIEF: InSilico jumps in Hong Kong trading debut
3696.HK
- BRIEF: InSilico gets CSRC nod for Hong Kong IPO
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
- Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
